Yu JS - Search Results

1

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.

Liu X, Xu Y, Xiong W, Yin B, Huang Y, Chu J, Xing C, Qian C, Du Y, Duan T, Wang HY, Zhang N, Yu JS, An Z, Wang R. Liu X, et al. Among authors: yu js. J Immunother Cancer. 2022 Mar;10(3):e004035. doi: 10.1136/jitc-2021-004035. J Immunother Cancer. 2022. PMID: 35338087 Free PMC article.

2

AIM-2: a novel tumor antigen is expressed and presented by human glioma cells.

Liu G, Yu JS, Zeng G, Yin D, Xie D, Black KL, Ying H. Liu G, et al. Among authors: yu js. J Immunother. 2004 May-Jun;27(3):220-6. doi: 10.1097/00002371-200405000-00006. J Immunother. 2004. PMID: 15076139

3

Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.

Ji J, Judkowski VA, Liu G, Wang H, Bunying A, Li Z, Xu M, Bender J, Pinilla C, Yu JS. Ji J, et al. Among authors: yu js. Stem Cells Transl Med. 2014 Mar;3(3):356-64. doi: 10.5966/sctm.2013-0135. Epub 2013 Dec 27. Stem Cells Transl Med. 2014. PMID: 24375541 Free PMC article.

4

A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.

Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, Wang H, Mazer M, Ganaway T, Chu RM, Patil CG, Black KL, Shiao SL, Wang R, Yu JS. Hu JL, et al. Among authors: yu js. Clin Cancer Res. 2022 Feb 15;28(4):689-696. doi: 10.1158/1078-0432.CCR-21-2867. Clin Cancer Res. 2022. PMID: 34862245 Clinical Trial.

5

Activated T cell therapy targeting glioblastoma cancer stem cells.

Miyaguchi K, Wang H, Black KL, Shiao SL, Wang R, Yu JS. Miyaguchi K, et al. Among authors: yu js. Sci Rep. 2023 Jan 5;13(1):196. doi: 10.1038/s41598-022-27184-w. Sci Rep. 2023. PMID: 36604465 Free PMC article.

6

Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL. Yu JS, et al. Cancer Res. 2001 Feb 1;61(3):842-7. Cancer Res. 2001. PMID: 11221866 Clinical Trial.

7

The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma.

Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS. Ehtesham M, et al. Among authors: yu js. Cancer Res. 2002 Oct 15;62(20):5657-63. Cancer Res. 2002. PMID: 12384520

8

Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats.

Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Ehtesham M, et al. Among authors: yu js. J Immunother. 2003 Mar-Apr;26(2):107-16. doi: 10.1097/00002371-200303000-00003. J Immunother. 2003. PMID: 12616102

9

Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma.

Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H. Liu G, et al. Among authors: yu js. J Immunother. 2003 Jul-Aug;26(4):301-12. doi: 10.1097/00002371-200307000-00002. J Immunother. 2003. PMID: 12843792

10

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.

Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Yu JS, et al. Cancer Res. 2004 Jul 15;64(14):4973-9. doi: 10.1158/0008-5472.CAN-03-3505. Cancer Res. 2004. PMID: 15256471 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,480 results

Search Page